Divis Laboratories Ltd
NSE: DIVISLAB BSE: 532488
₹5935
(-2.00)%
Mon, 02 Feb 2026, 05:07 am
Market Cap1607.21B
PE Ratio63.40
Dividend0.50
Health Technology
Pharmaceuticals: Major
24.5Kdivis laboratories ltd History
1990
- Divis Research Center (DRC) was established.
1991
- Divis Research Center successfully developed several commercial processes for intermediates and bulk actives and supplied to manufacturing majors.
1994
- Divis Research Center changed its name to Divis Laboratories Limited to reflect its growing area of operations and its plans to enter the manufacturing sector in the following year.
1995
- The Manufacturing Facility (Unit-1) at Choutuppal near Hyderabad started operations.
1997
- SGS-Yarsley of U.K certified Divis Laboratories as ISO-9002 compliant.
1999
- The European Directorate gave a 'Certificate of Suitability' (CoS) for Naproxen produced at Divis Laboratories.
2000
- The US-FDA successfully inspected Divis Laboratories.
- SGS-Yarsley of U.K awarded Divis the ISO 9001 Certification.
- SGS International AG of Switzerland awarded Divis the ISO-14001 Certification for its efficient Environment Management Systems.
2001
- BVQI of London awarded Divis the OHSAS-18001 Certification for its Occupational Health and Safety Management Systems.
2002
- Divis commenced the setting up of its 2nd Manufacturing Facility (Unit-2) at Chippada near Visakhapatnam.
2003
- Divi's Laboratories opened a new research center called 'DRC-Vizag' for fundamental research in selected niche business core segments.
- The Company went for an IPO and listed on stock exchanges BSE, NSE, and HSE.
- The Company received a Certificate of Substantiability from the Council of Europe.
- Mr. A Narendra was appointed as Company Secretary & Compliance Officer of the Company.
2004
- The manufacturing facility of Divi's Labs at Choutuppal near Hyderabad was successfully inspected by US-FDA in May 2004.
- The US-FDA inspected the Choutuppal (Unit-1) for a second time with no 483.
2006
- The Company delisted its equity shares from The Hyderabad Stock Exchange Ltd (HSE), Hyderabad with effect from March 29, 2006.
- The US-FDA inspected the Visakhapatnam (Unit-2) for the first time.
2007
- The Company split its face value from Rs10/- to Rs2/-.
2008
- The third US-FDA inspection for Choutuppal (Unit-1) took place.
2009
- The Company was certified and awarded for 'Best Green Belt Development'.
- The Company received the 'SURAKSHA PURASKAR' for the year 2008.
- The Company received the ISO 14001: 2004 re-certification for its Environment Management System.
- The Company gave a bonus in the ratio of 1:1.
2010
- Divis Lab set up a new unit in SEZ at Visakhapatnam.
- The Company recommended a dividend of 300% i.e. Rs. 6/- per equity share of Rs. 2/- face value for the year ended March 31, 2010.
2011
- Divi's Laboratories' stock surged 3.5 per cent in early morning trade on the Bombay Stock Exchange after the announcement of healthy growth in Q2 numbers.
2012
- The Board of Directors decided to seek shareholders' approval for the re-appointment and revision in remuneration of Mr. Madhusudana Rao Divi as Director-Projects of the Company.
- The Company re-appointed and revised the remuneration of Mr. Kiran S. Divi, Director & President-Operations of the Company.
- The remuneration of Dr. Murali K. Divi, Chairman & Managing Director of the Company, was enhanced.
- The remuneration of Mr. N. V. Ramana, Executive Director of the Company, was enhanced.
2013
- Divis Laboratories Ltd recommended a dividend of 750% i.e. Rs. 15/- per equity share of Rs. 2/- face value for the year ended March 31, 2013.
2014
- Divis Laboratories Ltd recommended a dividend of 1000% i.e. Rs. 20/- per equity share of Rs. 2/- face value for the year ended March 31, 2014.
2015
- Divis Laboratories Ltd approved the issuance of bonus shares on the eve of its 25th year of formation, in the ratio of 1:1.
2016
- Divis Labs unit-2 at Chippada was successfully inspected by USFDA.
2017
- Divi's Laboratories reached a milestone of 11,000 employees and became one of the largest employers in the combined state of Telangana/Andhra Pradesh.
- Divi's Laboratories became one of the top 3 API manufacturers in the world and one of the top API companies in Hyderabad.
2018
- Divi's Laboratories' market capital reached $5B.
- The product portfolio was expanded to over 30 products.
- Divi's Laboratories' stock climbed nearly 2% on a rating upgrade.
2019
- Divi's Laboratories approved an additional investment of $250M towards expansion of production blocks in Unit-I and Unit-II.
- The 7th USFDA inspection in Unit 2 took place.
2020
- Commissioning of new production blocks in DC SEZ at Unit-I and DCV SEZ at Unit-II occurred.
- US-FDA inspection of Unit-II at Village Chippada, Andhra Pradesh took place.
- Commencement of commercial production from DCV-SEZ Unit began.
- Construction of Divi's Laboratories Unit-III Facility near Kakinada commenced.
2021
- Ground breaking of the manufacturing plant in Kakinada took place.
2022
- Divi's Laboratories received the EHS excellence Award.
- Divi's Laboratories reached the milestone of being one among the top 3 API manufacturers in the world and one among the top API companies in Hyderabad.
2024
- Divi's Laboratories has a global presence in supplying APIs to more than 100 countries.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800